Stockreport

Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation

Frequency Therapeutics, Inc.  (FREQ) 
PDF WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repa [Read more]